Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25951805 | 0.93 | LRRK2 (0.87) | LRRK2TTK | |
| SCHEMBL25951726 | 0.93 | LRRK2 (0.86) | LRRK2TTK | |
| SCHEMBL7453585 | 0.92 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7446915 | 0.92 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL14995464 | 0.92 | LRRK2 (0.94) | LRRK2TTK | |
| SCHEMBL15033139 | 0.92 | LRRK2 (0.88) | LRRK2TTK | |
| SCHEMBL7454471 | 0.92 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL7450006 | 0.92 | LRRK2 (1.00) | LRRK2TTK | |
| SCHEMBL15003190 | 0.91 | LRRK2 (0.89) | LRRK2TTK | |
| SCHEMBL12067609 | 0.91 | LRRK2 (1.00) | LRRK2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110678182-B | Pharmaceutical composition containing a compound capable of penetrating the blood-brain barrier as an active ingredient for preventing or treating brain cancer | 大邱庆北尖端医疗产业振兴财团 | 2022-08-23 | — | — | CN | claimed |
| EP-3075730-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-10-05 | — | — | EP | claimed |
| EP-2576541-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | HOFFMANN LA ROCHE (CH) | 2016-04-06 | — | — | EP | claimed |
| US-9139566-B2 | Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (PET) imaging for LRRK2 | GENENTECH, INC. (US) | 2015-09-22 | — | — | US | claimed |
| EP-2576541-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-04-10 | — | — | EP | claimed |
| US-8354420-B2 | Aminopyrimidine derivatives as LRRK2 inhibitors | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | claimed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | NATIONAL CANCER CENTER (KR) | 2023-08-10 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) | 2023-06-15 | — | — | US | disclosed |
| US-11661461-B2 | Phospho-Rab antibodies, assays and methods of use thereof | DENALI THERAPEUTICS INC. (US) | 2023-05-30 | — | — | US | disclosed |
| WO-2012075046-A9 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012075046-A1 | ASSAYS AND BIOMARKERS FOR LRRK2 | GENENTECH, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | LRRK2 1/4885TTK 3237/4885 |
| US-11661461-B2 | Phospho-Rab antibodies, assays and methods of use thereof | RAB10, GTPBP10, RAB8A | LRRK2 19/4885TTK 331/4885 |
| US-20230248740-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885TTK 3278/4885 |
| US-20230181596-A1 | Pharmaceutical Composition Comprising Compound Capable of Penetrating Blood-Brain Barrier as Effective Ingredient for Preventing or Treating Brain Cancer | LRRK2, FABP7, PARK7 | LRRK2 1/4885TTK 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.